OmniAb (NASDAQ: OABI) — Perfil da empresa, notícias e dados financeiros
OmniAb specializes in developing antibody-based therapeutics, focusing on oncology and immunology through innovative technology.
OmniAb
OmniAb (NASDAQ:OABI) specializes in leveraging its proprietary technology to discover and develop innovative antibody-based therapeutics for a broad range of diseases. The company thrives on a dynamic platform that includes advanced genetic engineering, immunization, and screening technologies designed to address complex therapeutic challenges. OmniAb's operations revolve around partnerships and collaborations with biopharmaceutical entities, with a mission to expedite the journey from discovery to clinical stages. The company's projects span oncology, immunology, and infectious diseases among other areas, showcasing a versatile and potent approach to tackling severe health issues. Objectively, OmniAb aims to harness its cutting-edge technology to push the boundaries of antibody therapy, optimizing efficacy, safety, and accessibility for patients worldwide.
Resumo
Operações
Produtos e/ou serviços de OmniAb
- Antibody discovery platform leveraging transgenic animals for developing human therapeutic antibodies with diverse and optimized immune repertoire.
- Humanized rodent models designed to produce a broad diversity of high-affinity human antibodies, facilitating rapid discovery and development of therapeutic candidates.
- Modular OmniRat, OmniMouse, and OmniFlic platforms, offering diverse options for monoclonal antibody development against challenging targets in multiple therapeutic areas.
- OmniChicken platform, providing unique capabilities for generating antibodies with high specificity and affinity, suitable for a variety of therapeutic applications.
- OmniClic, a specialized platform for the generation of bispecific antibodies, enhancing therapeutic potential through targeted dual-action mechanisms.
- Integrated antibody discovery and optimization services, supporting partners from early-stage research through to pre-clinical development.
equipe executiva do OmniAb
- Matthew W. FoehrPresident, CEO & Director
- Kurt A. GustafsonExecutive VP of Finance & CFO
- Charles S. BerkmanChief Legal Officer
- Amechi NwachukuExecutive VP & Chief Operating Officer
- Cia McCaffreySenior Vice President of People & Talent
- Bill HarrimanSenior Vice President of Discovery Partnership Mgt., Technology Development & Operations
- Christel IfflandSenior Vice President of R&D Portfolio Management and Technology Operations
- Yasmina Noubia AbdicheSenior Vice President of Exploratory Research
- Bob ChenSenior Vice President of Discovery Systems
- Todd PettingillVice President of Business Development & Strategy
Últimas notícias sobre a OmniAb
Principais indicadores financeiros
Resultados divulgados pela OmniAb, em USD.
- Cap. de mercado
- 721,1 mi
- Receita (TTM)
- 38,5 mi
- P/L
- —
- LPA (diluído, TTM)
- -0.4
- Dividend yield
- —
- Margem de lucro
- -115.1%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 18,7 mi | -71,5 mi | -64,8 mi | |
| 26,4 mi | -74,5 mi | -62 mi | |
| 34,2 mi | -69,4 mi | -50,6 mi | |
| 59,1 mi | -26,6 mi | -22,3 mi |